19 May 2013
Keywords: crucell, buy, sbl, vaccin, 6m, dutch, biotechnology
Article | 27 November 2006
Dutch biotechnology company Crucell NV has signed an agreement for the acquisition of Stockholm, Sweden-based SBL Vaccin AB for a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 November 2006
4 December 2006
17 May 2013
© 2013 thepharmaletter.com